Why BioCryst Pharmaceuticals Rose 8% on Thursday
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) rose after the company's second-quarter earnings call. A stronger than expected performance from the company's shiny new sales force drove the biotech stock 8.7% higher as of 3:58 p.m EDT on Thursday.
Last December, the FDA approved BioCryst Pharmaceuticals' first drug, an oral treatment for hereditary angioedema (HAE) called Orladeyo. Takeda (NYSE: TAK) already markets a blockbuster injectable treatment for HAE patients and it was expected to pressure BioCryst's first drug launch.
Image source: Getty Images.
Source Fool.com
